3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Neoplasms
3
Lymphoma
3
Preleukemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Precancerous Conditions
2
Neoplasms by Histologic Type
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphoid
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Biphenotypic, Acute
2
Leukemia, B-Cell
2
Leukemia
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Diseases
2
Esophageal Neoplasms
2
Bone Marrow Diseases
2
Sarcoma
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Second Primary
1
Neoplasms, Plasma Cell
1
Interventions
lutetium Lu 177 dotatate
20
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
amino-acid, glucose, and electrolyte solution
4
Capecitabine
4
olaparib
3
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Patient Reported Outcome Measures
×
1 year
×
Clear all
No trials found.